Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Insulet (PODD)
NASDAQ:PODD
Holding PODD?
Track your performance easily
PODD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$125.82 - $243.98
Previous Close$235.54
Volume522.43K
Average Volume (3M)752.52K
Market Cap
$16.52B
Enterprise Value$17.09B
Total Cash (Recent Filing)$821.00M
Total Debt (Recent Filing)$1.40B
Price to Earnings (P/E)42.8
Beta0.89
Next Earnings
Oct 31, 2024EPS Estimate
$0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.51
Shares Outstanding70,115,482
10 Day Avg. Volume846,892
30 Day Avg. Volume752,516
Standard Deviation0.12
R-Squared0.28
Alpha-0.00353
Financial Highlights & Ratios
Price to Book (P/B)16.54
Price to Sales (P/S)8.76
Price to Cash Flow (P/CF)42.50
P/FCF Ratio57.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue9.13
Enterprise Value/Gross Profit14.74
Enterprise Value/Ebitda107.83
Forecast
1Y Price Target
$241.20Price Target Upside2.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
Insulet News
Bulls Say, Bears Say
Bulls Say
FDA ClearanceOmnipod 5 (O5) automated insulin delivery system (AID) received FDA clearance for Type 2 diabetics, making it the first and only AID system cleared for both T1D and T2D.
Market ExpansionThe label expansion will allow Insulet to directly market the product to patients with Type 2 diabetes, driving significant adoption in this population.
Sales And MarketingIncreased confidence in new start growth, driven by leveraging existing prescribers, initiating DTC advertising, and expanding the sales force.
Bears Say
MarginsGross margin and operating margin were hurt by an inventory charge of $13.5M relating to the decision to go to market in type 2 with Omnipod 5.
New Patient StartsNew patient starts were likely down slightly year-over-year globally and approximately 10% in the U.S. off all-time highs.
Product AvailabilityPODD now expects a less aggressive ramp in new prescriptions due to lower-than-expected competitor conversions and limited availability of G7 compatible Omnipod 5 in the retail pharmacy channel.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
PODD FAQ
What was Insulet’s price range in the past 12 months?
Insulet lowest stock price was $125.82 and its highest was $243.98 in the past 12 months.
What is Insulet’s market cap?
Currently, no data Available
When is Insulet’s upcoming earnings report date?
Insulet’s upcoming earnings report date is Oct 31, 2024 which is in 42 days.
How were Insulet’s earnings last quarter?
Insulet released its earnings results on Aug 08, 2024. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $0.564 by $2.026.
Is Insulet overvalued?
According to Wall Street analysts Insulet’s price is currently Undervalued.
Does Insulet pay dividends?
Insulet does not currently pay dividends.
What is Insulet’s EPS estimate?
Insulet’s EPS estimate is $0.79.
How many shares outstanding does Insulet have?
Insulet has 70,115,480 shares outstanding.
What happened to Insulet’s price movement after its last earnings report?
Insulet reported an EPS of $2.59 in its last earnings report, beating expectations of $0.564. Following the earnings report the stock price went down -8.809%.
Which hedge fund is a major shareholder of Insulet?
Among the largest hedge funds holding Insulet’s share is PRIMECAP Management Co. It holds Insulet’s shares valued at 117M.
---
Insulet Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$241.20 (2.16% Upside)
$241.20 (2.16% Upside)
Blogger Sentiment
Bullish
PODD Sentiment 75%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 919.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
38.81%
12-Months-Change
Fundamentals
Return on Equity
50.93%
Trailing 12-Months
Asset Growth
20.78%
Trailing 12-Months
Company Description
Insulet
Insulet Corp. is a medical device company. The firm engages in the development, manufacture and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.
---
PODD Company Deck
---
PODD Earnings Call
Q2 2024
0:00 / 0:00
---
PODD Revenue Breakdown
73.71% U.S. Omnipod
24.16% International Omnipod
2.12% Drug Delivery
---
PODD Stock 12 Month Forecast
Average Price Target
$241.20
▲(2.16% Upside)
Technical Analysis
Best Analysts Covering PODD
1 Year
1 Year Success Rate
11/12 ratings generated profit
1 Year Average Return
+31.67%
assigned a buy rating 23 days ago
Copying Matthew Taylor's trades and holding each position for 1 Year would result in 91.67% of your transactions generating a profit, with an average return of +31.67% per trade.
---